PURPOSE OF REVIEW: Anaplastic large cell lymphomas (ALCLs) are rare entities whose somatic genetic lesions have been identified only in a subset of patients. Thus, an integrated and massive discovery programme is required to define their tumourigenic alterations and to design more successful tailored therapies. RECENT FINDINGS: The discovery of anaplastic lymphoma kinase (ALK) fusions has provided the basis for the characterization of distinct subsets among ALCL patients. Although the oncogenic addiction of ALK signalling is proven, the tumorigenic contribution of coactivating lesions is still missing. As ALK- and ALK+ share common signatures, it is plausible that analogous mechanisms of transformation may be operating in both subsets, as confirmed by the dysregulated activation of c-MYC, RAS and NFκB, and the loss of Blimp-1 and p53/p63 axis. Nonetheless, recurrent genetic alterations for ALK- ALCL or refractory leukaemic ALK+ ALCL are lacking. Moreover, although conventional chemotherapies (anthracycline-based) are most successful, that is in ALK+ ALCL patients, the implementation of ALK inhibitors or of anti-CD30 based treatments provides innovative solutions, particularly in paediatric ALK+ ALCL and in chemorefractory/relapsed patients. SUMMARY: The complete portrayal of the landscape of genetic alterations in ALCL will dictate the development of innovative chemotherapeutic and targeted therapies that will fit most with the molecular and clinical profiling of individual patients.

Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma.

TABBO', FABRIZIO;INGHIRAMI, Giorgio;
2013

Abstract

PURPOSE OF REVIEW: Anaplastic large cell lymphomas (ALCLs) are rare entities whose somatic genetic lesions have been identified only in a subset of patients. Thus, an integrated and massive discovery programme is required to define their tumourigenic alterations and to design more successful tailored therapies. RECENT FINDINGS: The discovery of anaplastic lymphoma kinase (ALK) fusions has provided the basis for the characterization of distinct subsets among ALCL patients. Although the oncogenic addiction of ALK signalling is proven, the tumorigenic contribution of coactivating lesions is still missing. As ALK- and ALK+ share common signatures, it is plausible that analogous mechanisms of transformation may be operating in both subsets, as confirmed by the dysregulated activation of c-MYC, RAS and NFκB, and the loss of Blimp-1 and p53/p63 axis. Nonetheless, recurrent genetic alterations for ALK- ALCL or refractory leukaemic ALK+ ALCL are lacking. Moreover, although conventional chemotherapies (anthracycline-based) are most successful, that is in ALK+ ALCL patients, the implementation of ALK inhibitors or of anti-CD30 based treatments provides innovative solutions, particularly in paediatric ALK+ ALCL and in chemorefractory/relapsed patients. SUMMARY: The complete portrayal of the landscape of genetic alterations in ALCL will dictate the development of innovative chemotherapeutic and targeted therapies that will fit most with the molecular and clinical profiling of individual patients.
20
4
374
381
Fabrizio Tabbò; Maurilio Ponzoni; Raul Rabadan; Francesco Bertoni; Giorgio Inghirami; European T-cell Lymphoma Study Group; (Sabrina Aliberti; Antonella Barreca; Luca Bessone; Ramona Crescenzo; Filomena Di Giacomo; Marcello Gaudiano; Indira Landra; Elena Lasorsa; Rodolfo Machiorlatti; Elisabetta Mereu; Katia Messana; Domenico Novero; Elisa Pellegrino; Achille Pich; Roberto Piva; Irene Scarfo’; Elisa Spaccarotella; Maria Todaro; Ivana Ubezzi; Susanna Urigu; Francesco Vittone; Francesco Abate; Elisa Ficarra; Andrea Acquaviva; Carmelo Carlo-Stella; Claudio Agostinelli; Pier Paolo Piccaluga; Stefano Pileri; Brunangelo Falini; Enrico Tiacci; Michela Boi; Ivo Kwee)
File in questo prodotto:
File Dimensione Formato  
Curr_Opin_Hematol_ 2013Copy.pdf

Accesso aperto con embargo fino al 31/07/2014

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 312.73 kB
Formato Adobe PDF
312.73 kB Adobe PDF Visualizza/Apri
Curr Opin Hematol 2013; 20,374-81 Beyond NPM-anaplastic lymphoma .pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 364.09 kB
Formato Adobe PDF
364.09 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/136676
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 13
social impact